# Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)

> **NCT04980833** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 41 (actual)

## Conditions studied

- PIK3CA-related Overgrowth Spectrum (PROS)

## Interventions

- **DRUG:** Alpelisib

## Key facts

- **NCT ID:** NCT04980833
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-27
- **Primary completion:** 2027-08-20
- **Final completion:** 2027-08-20
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04980833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04980833, "Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT04980833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*